Abstract:Question Does the presence of cerebral microbleeds (CMBs) modify the effect of rivaroxaban, 15 mg, compared with aspirin, 100 mg, daily in patients with embolic stroke of undetermined source (ESUS)?Findings In this analysis of a randomized clinical trial that included 3699 patients with ESUS, those with CMBs had higher rates of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality during 11 months of follow-up. There was, however, no treatment effect modification observed with CMBs for these outcomes.Meaning In this study, CMBs marked an increased risk of adverse clinical outcomes in ESUS but did not appear to influence the effects of rivaroxaban.Importance The reported associations of cerebral microbleeds with recurrent stroke and intracerebral hemorrhage have raised concerns regarding antithrombotic treatment in patients with a history of stroke and microbleeds on magnetic resonance imaging.Objective To characterize microbleeds in embolic strokes of undetermined source (ESUS) and report interactions between microbleeds and the effects of random assignment to anticoagulant vs antiplatelet therapy.Design, Setting, and Participants Subgroup analyses of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) international, double-blind, randomized, event-driven phase 3 clinical trial. Participants were enrolled between December 2014 and September 2017 and followed up for a median of 11 months. The study setting included 459 stroke recruitment centers in 31 countries. Patients aged 50 years or older who had neuroimaging-confirmed ESUS between 7 days and 6 months before screening were eligible. Of these 7213 NAVIGATE ESUS participants, 3699 (51%) had information on cerebral microbleeds reported on their baseline clinical magnetic resonance imaging and were eligible for these analyses. Patients with a prior history of symptomatic intracerebral hemorrhage were excluded from the NAVIGATE ESUS trial.Interventions Rivaroxaban, 15 mg, compared with aspirin, 100 mg, daily.Main Outcomes and Measures The primary outcome was recurrent stroke. Secondary outcomes were ischemic stroke, intracerebral hemorrhage, and all-cause mortality.Results Microbleeds were present in 395 of 3699 participants (11%). Of patients with cerebral microbleeds, mean (SD) age was 69.5 (9.4) years, 241 were men (61%), and 201 were White (51%). Advancing age (odds ratio [OR] per year, 1.03; 95% CI, 1.01-1.04), East Asian race/ethnicity (OR, 1.57; 95% CI, 1.04-2.37), hypertension (OR, 2.20; 95% CI, 1.54-3.15), multiterritorial infarcts (OR, 1.95; 95% CI, 1.42-2.67), chronic infarcts (OR, 1.78; 95% CI, 1.42-2.23), and occult intracerebral hemorrhage (OR, 5.23; 95% CI, 2.76-9.90) were independently associated with microbleeds. The presence of microbleeds was associated with a 1.5-fold increased risk of recurrent stroke (hazard ratio [HR], 1.5; 95% CI, 1.0-2.3), a 4-fold risk of intracerebral hemorrhage (HR, 4.2; 95% CI, 1.3-13.9), a 2-fold risk of all-cause mortality (HR, 2.1; 95% CI, 1.1-4.3), and strictly lobar microbleeds with an approximately 2.5-fold risk of ischemic stroke (HR, 2.3; 95% CI, 1.3-4.3). There were no interactions between microbleeds and treatment assignments for recurrent stroke, ischemic stroke, or all-cause mortality. The HR of intracerebral hemorrhage on rivaroxaban was similar between persons with microbleeds (HR, 3.1; 95% CI, 0.3-30.0) and persons without microbleeds (HR, 3.0; 95% CI, 0.6-14.7; interaction P = .97).Conclusions and Relevance Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality in ESUS but do not appear to influence effects of rivaroxaban on clinical outcomes.Trial Registration <a href="https://clinicaltrials.gov/ct2/show/NCT02313909">ClinicalTrials.gov Identifier: NCT02313909</a>

Effect of microbleeds on prognosis of stroke patients receiving thrombolysis:a systemic review and meta-analysis

Clinical Outcome in Acute Ischemic Stroke Patients with Microbleeds after Thrombolytic Therapy A Meta-Analysis

Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis.

[Impact of Cerebral Microbleeds on Outcomes of Acute Ischemic Stroke Treated with Intravenous Thrombolysis].

New microbleeds after thrombolysis: contiguous thin-slice 3T MRI.

Extensive Cerebral Microbleeds Predict Parenchymal Haemorrhage and Poor Outcome after Intravenous Thrombolysis

[Safety of Intravenous Thrombolysis in Cerebral Microbleeds Patients with Prior Antiplatelet Therapy].

Effect of Baseline Infarct Size on Endovascular Thrombectomy with or Without Intravenous Alteplase in Stroke Patients: A Subgroup Analysis of a Randomized Trial (DIRECT-MT).

Effect of Bleeding Risk Prediction on Decision Making of Intravenous Thrombolysis Before Thrombectomy: a Subgroup Analysis of DIRECT-MT.

The Presence of Previous Cerebral Microbleeds Has a Negative Effect on Hypertensive Intracerebral Hemorrhage Recovery

Impact of Cerebral Microbleeds in Stroke Patients with Atrial Fibrillation

Use of anticoagulant therapy and cerebral microbleeds: a systematic review and meta-analysis

Effect of Tirofiban on new cerebral microbleeds after mechanical thrombectomy in patients with acute ischemic stroke

Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source

Influence of cerebral microbleeds on mechanical thrombectomy outcomes

Editors' Note: Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial

Author Response: Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial

Prevalence, risk factors, and clinical outcomes of remote intracerebral hemorrhage after intravenous thrombolysis in acute ischemic stroke: a systematic review and meta-analysis

Hemorrhagic risk after intravenous thrombolysis for ischemic stroke in patients with cerebral microbleeds and white matter disease

Factors associated with symptomatic intracranial haemorrhage after intravenous thrombolysis in severe white matter lesions: a retrospective analysis

Meta-Analysis of the Effectiveness and Safety of Intravenous Thrombolysis in Patients with Acute Cerebral Infarction